Skip to main content
LabGenomics. Co., Ltd. logo

LabGenomics. Co., Ltd. — Investor Relations & Filings

Ticker · 084650 ISIN · KR7084650001 KO Human health and social work activities
Open in API
Filings indexed 370 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 084650

About LabGenomics. Co., Ltd.

http://www.labgenomics.co.kr/

LabGenomics is a biotechnology company specializing in molecular diagnostics and genetic analysis. The company's core activities are structured around three primary areas: diagnostic services, Next-Generation Sequencing (NGS), and the development and manufacturing of in-vitro diagnostic (IVD) products. It provides a comprehensive range of services, including general diagnostics, sample analysis, prenatal malformation testing, and cancer genetic testing. In addition to services, LabGenomics develops and sells diagnostic kits and devices, with a focus on applications for infectious diseases. The company is actively engaged in research and development to create innovative biotechnology products and is pursuing a global expansion strategy, notably through the acquisition of CLIA-certified laboratories to enhance its service capabilities.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제 25기) 2026년 01월 01일~2026년 03월 31일” and contains detailed financial data, business overview, capital changes, share information, and other substantive interim financial statements and disclosures for the first quarter of fiscal year 2026. It is the full quarterly report itself, not a brief announcement or regulatory filing notice. Under the classification scheme, this corresponds to an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 88% confidence The document is a ‘주요사항보고서’ filed with the Financial Supervisory Service/Korea Exchange announcing the decision to issue convertible bonds, detailing the bond terms, interest, conversion pricing, investor, use of proceeds, collateral, etc. This is a direct financing activity (debt and capital structure update) rather than an annual report, earnings release, or internal management report. Therefore it falls under Capital/Financing Update (CAP).
2026-05-13 Korean
소속부변경
Regulatory Filings
2026-04-30 Korean
기타경영사항(자율공시) (업무제휴계약 체결)
Regulatory Filings Classification · 85% confidence The document is a voluntary regulatory disclosure (자율공시) of a business cooperation agreement (업무제휴계약 체결) by LabGenomics. It is not an earnings release, annual or interim report, or any other specific filing type such as capital change or board appointment. It therefore falls into the general ‘Regulatory Filings’ category (RNS) as a miscellaneous corporate announcement on the exchange.
2026-04-01 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 93% confidence The document is a regulatory notice filed with the Financial Services Commission/Korea Exchange regarding the appointment, reappointment, or resignation of an outside (independent) director. It details the changes in board composition and director profile. This matches the ‘Board/Management Information’ category for announcements of board changes.
2026-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official results of the company’s Annual General Meeting (정기주주총회 결과), showing each resolution (e.g. approval of financial statements, director elections, remuneration limits) with vote counts and percentages. It provides detailed voting outcomes for shareholder proposals. This clearly matches the definition of a Declaration of Voting Results (Code: DVA).
2026-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.